









Markets
/
Stocks
/
nasdaq-bmrn
/

BioMarin Pharmaceutical Inc

BMRN

58.130USD

+0.980+1.71%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

11.17BMarket Cap

21.38P/E TTM



BioMarin Pharmaceutical Inc

58.130

+0.980+1.71%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioMarin Pharmaceutical Inc

Currency: USD Updated: 2026-02-06

Key Insights

BioMarin Pharmaceutical Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 43 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 90.89.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioMarin Pharmaceutical Inc's Score

Industry at a Glance

Industry Ranking

43 / 159

Overall Ranking

120 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioMarin Pharmaceutical Inc Highlights

StrengthsRisks

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 36.16% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.85B.

Undervalued

The company’s latest PE is 21.38, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 187.90M shares, increasing 0.04% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 17.35K shares of this stock.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

92.472

Target Price

+60.49%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of BioMarin Pharmaceutical Inc is 7.55, ranking 108 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 776.13M, representing a year-over-year increase of 4.08%, while its net profit experienced a year-over-year increase of 128.98%.

Score

Industry at a Glance

Previous score

7.55

Change



Financials

8.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.72

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.40

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioMarin Pharmaceutical Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of BioMarin Pharmaceutical Inc is 6.79, ranking 112 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 21.38, which is 1134.83% below the recent high of 263.97 and 28.43% above the recent low of 15.30.

Score

Industry at a Glance

Previous score

6.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 43/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of BioMarin Pharmaceutical Inc is 8.08, ranking 54 out of 159 in the Pharmaceuticals industry. The average price target is 91.50, with a high of 122.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

8.08

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

92.472

Target Price

+60.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

BioMarin Pharmaceutical Inc

BMRN

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of BioMarin Pharmaceutical Inc is 7.36, ranking 63 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 61.27 and the support level at 54.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.13

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.149

Buy

RSI(14)

55.243

Neutral

STOCH(KDJ)(9,3,3)

71.476

Neutral

ATR(14)

1.538

Low Volatility

CCI(14)

115.603

Buy

Williams %R

13.419

Overbought

TRIX(12,20)

-0.014

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

57.692

Buy

MA10

57.230

Buy

MA20

56.819

Buy

MA50

56.589

Buy

MA100

55.143

Buy

MA200

56.611

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of BioMarin Pharmaceutical Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 108.82%, representing a quarter-over-quarter decrease of 2.08%. The largest institutional shareholder is The Vanguard, holding a total of 18.07M shares, representing 9.41% of shares outstanding, with 4.66% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

18.49M

-2.22%

BlackRock Institutional Trust Company, N.A.

17.25M

-4.38%

PRIMECAP Management Company

Star Investors

15.23M

-3.44%

Dodge & Cox

Star Investors

14.69M

-2.79%

State Street Investment Management (US)

8.76M

-0.94%

Viking Global Investors LP

Star Investors

8.32M

-32.28%

AQR Capital Management, LLC

5.93M

+6.30%

Geode Capital Management, L.L.C.

3.54M

+1.95%

Rothschild & Co Asset Management Europe SCS

2.63M

+13.74%

Millennium Management LLC

2.63M

-7.31%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioMarin Pharmaceutical Inc is 7.23, ranking 40 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.